Mitral Regurgitation News and Research

RSS

Penn researchers explore possibilities to improve outcomes in low flow AS patients treated with TAVR

Aortic stenosis (AS), the narrowing of the aortic valve in the heart which causes restricted blood flow, is one of the most common and serious valve disease problems. For patients with one type of AS - low flow - transcatheter aortic valve replacement (TAVR), a minimally invasive procedure which corrects the damaged aortic valve, is often the best option for restoring the heart's normal pumping function.

16 Jun 2016

Patients undergoing mini-MVR have similar outcomes compared with conventional surgery

Patients undergoing minimally invasive mitral valve repair or replacement (mini-MVR) have similar outcomes as patients undergoing conventional surgery and also experience shorter hospital stays and fewer blood transfusions, according to an article posted online today by The Annals of Thoracic Surgery.

31 Mar 2016

Boston Scientific closes additional financing with MValve Technologies

Boston Scientific Corporation today announced that it has closed on an additional round of financing with MValve Technologies Ltd., a developer of a percutaneous mitral valve replacement system, designed to work with the Boston Scientific LOTUS Valve, creating a unique mitral regurgitation (MR) treatment solution.

8 Oct 2015

Novel prosthetic heart valve developed for treatment of mitral regurgitation

A team of researchers from the National University of Singapore (NUS) has developed a novel prosthetic heart valve, known as VeloX, which can be implanted through a small incision for the treatment of a serious heart valve disorder called mitral regurgitation. This is a condition in which the mitral valve on the left side of the heart does not close properly. The device is particularly beneficial to patients who are of high surgical risk or are unsuitable for existing clinical interventions.

6 Oct 2015

Valtech receives CE Mark approval for Cardioband Mitral Reconstruction System

Valtech Cardio, Ltd.,, an innovator in the development of devices for mitral and tricuspid valve repair and replacement, announced today it has received Conformite Europeenne (CE) Marking for its Cardioband Mitral Reconstruction System (Cardioband), a proprietary, implantable mitral reconstruction device with a transfemoral, transseptal delivery system for mitral valve repair.

14 Sep 2015

Training session can improve cardiologists’ ability to detect basic and advanced murmurs

Cardiologists failed to identify more than half of basic and about 35 percent of advanced pre-recorded murmurs, but skills improved after a 90 minute training session, according to research presented today at the European Society of Cardiology Congress 2015.

1 Sep 2015

New supercomputer models can capture the behavior of human heart valves

New supercomputer models have come closer than ever to capturing the behavior of normal human heart valves and their replacements, according to recent studies by groups including scientists at the Institute for Computational Engineering and Sciences at The University of Texas at Austin and the Department of Mechanical Engineering at Iowa State University.

20 Aug 2015

Delaying surgery until clinical triggers emerge leads to increased mortality in patients with mitral regurgitation

Patients with mitral regurgitation face a dilemma of whether to undergo corrective surgery early, when they might have no or few symptoms, or wait until their condition worsens. Current guidelines allow for watchful waiting until certain symptoms appear that would then "trigger" the decision to proceed with surgery.

12 Aug 2015

St. Luke’s surgeons first to perform percutaneous Mitral Valve Repair using MitraClip technology

Arthur Decheser said the “doctors were dancing” last week after they successfully used a new device to stop his mitral valve from leaking.

11 Aug 2015

Neovasc's second quarter revenues drop 18%

Neovasc Inc. today announced financial results for the quarter ended June 30, 2015.

6 Aug 2015

CardiAQ Valve Technologies announces first human implant of transcatheter bioprosthetic mitral heart valve

CardiAQ Valve Technologies (CardiAQ), which has developed the world’s first self-conforming and self-anchoring technology for nonsurgical transfemoral-transseptal percutaneous Transcatheter Mitral Valve Implantation (TMVI), today announced that its second-generation bioprosthetic mitral heart valve was successfully implanted as a compassionate treatment into a 72-year-old male suffering from severe mitral regurgitation (MR 4+) with multiple co-morbidities and ineligible for alternate treatment modalities.

24 Jun 2015

Transcatheter MitraClip system safe, effective for valve repair treatment

The commercial track record with transcatheter mitral valve repair, approved for patients at high risk for surgery, compares favorably with pre-approval reports, according to findings from a U.S. registry presented at the American College of Cardiology's 64th Annual Scientific Session.

18 Mar 2015

Study shows heart valve repair can benefit patients with mitral regurgitation

Patients with severe mitral regurgitation (MR) often suffer from psycho-emotional symptoms, such as depression and anxiety, but after undergoing mitral valve repair surgery patients experience a marked improvement in emotional and physical wellbeing, according to an article in the March 2015 issue of The Annals of Thoracic Surgery.

2 Mar 2015

Tendyne Feasibility Study: Tendyne successfully implants TMVI system in first patient

Tendyne Holdings, Inc., a privately held clinical stage medical device company, announced today that in November 2014 the Tendyne Transcatheter Mitral Valve Implantation system (TMVI) was successfully implanted in the first patient of the Tendyne Feasibility Study. This was the first patient enrolled in a three continent, multicenter trial, which aims to generate insight into the safety and performance of the Tendyne device in inoperable patients suffering from mitral regurgitation.

15 Dec 2014

Neovasc gets conditional IDE approval from FDA to initiate trial for Tiara mitral valve system

Neovasc Inc. today announced that it has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company's Tiara™ transcatheter mitral valve.

9 Oct 2014

Cardiac Dimensions adds $8.5M to its previously announced financing

Cardiac Dimensions® today announced the addition of $8.5 million to its previously announced financing.

7 Oct 2014

CardiAQ performs first-in-human Trans-Apical TMVI procedure

CardiAQ Valve Technologies (CardiAQ), which performed the first ever Trans-Femoral, Transcatheter Mitral Valve Implantation procedure in June of 2012 with its self-conforming, self-anchoring implant technology, announced today that it has achieved another milestone in cardiovascular medicine by successfully implanting its Second Generation Transcatheter Mitral Valve in an 88-year-old female suffering from severe mitral regurgitation (MR 4+) using the company's newly added Trans-Apical Delivery System.

20 May 2014

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

OPKO Health, Inc., a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its 2013 fourth quarter and full year ended December 31, 2013.

4 Mar 2014

MHIF creates scientific program to address gaps in treating valvular heart disease patients

Despite significant medical advances, there continue to be significant gaps in the health care of the growing number of patients with valvular heart disease. In the USA, the total number of people aged 65 years or older with valvular heart disease will grow to approximately 5.2 million by year 2020, and 6.8 million individuals by the year 2030. The Minneapolis Heart Institute Foundation- has created a scientific program, "Valve Summit 2014: The Science and Delivery of Optimal, Multi-Disciplinary Care," to address the ongoing, complex evolution in the clinical management of patients with valvular heart disease. The conference will be held on April 25th and 26th at the Radisson Blu in downtown Minneapolis.

4 Dec 2013

AATS, cardiovascular professional societies release overview of transcatheter therapies for mitral regurgitation

AATS and three cardiovascular professional societies today released an overview of transcatheter therapies for mitral regurgitation.

26 Nov 2013